KKR to Acquire PRA International

Global investment firm KKR  (NYSE: KKR  ) is acquiring global contract research organization PRA International from San Francisco-based private equity firm Genstar Capital for an undisclosed sum, PRA announced today. The New York Times reports that a "person briefed on the matter" said the price was about $1.3 billion.

PRA is one of the world's biggest CROs with more than 5,300 employees located in more than 50 offices worldwide, performing approximately 2,000 clinical trials in more than 80 countries for more than 300 clients since 2000.

That was underlined by KKR Health Care investing team member Jim Momtazee, who was quoted as saying, "As one of the fastest growing companies in the CRO sector, PRA is known for its strong client relationships and differentiated therapeutic expertise."

The services PRA provides on a contract basis to the pharmaceutical and biotechnology industries include filing Investigational New Drug and similar regulatory applications, management and implementation of phase I through IV clinical trials, preparation and submission of New Drug Applications, and post-marketing surveillance.

Genstar acquired PRA in 2007 for $797 million. Earlier this year it put the CRO up for auction following a failed effort to obtain a sufficient price two years ago. Had it failed to attract enough attention again, Genstar was considering putting PRA up for an IPO.

The transaction announced today is expected to close in the third quarter of 2013, subject to regulatory approvals and other customary closing conditions.

Jefferies LLC acted as exclusive financial advisor and Latham & Watkins acted as legal advisor to PRA. Credit Suisse, UBS's investment bank, and Wells Fargo Securities division served as financial advisors to KKR. Simpson Thacher & Bartlett  served as legal counsel to KKR. Fully committed debt financing will be provided by Credit Suisse, Jefferies, UBS Investment Bank, and KKR Capital Markets.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2506151, ~/Articles/ArticleHandler.aspx, 9/27/2016 5:06:56 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 7 hours ago Sponsored by:
DOW 18,094.83 -166.62 -0.91%
S&P 500 2,146.10 -18.59 -0.86%
NASD 5,257.49 -48.26 -0.91%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 4:02 PM
KKR $14.07 Down -0.27 -1.88%
KKR and Co. CAPS Rating: ****
CS $13.07 Down -0.35 -2.61%
Credit Suisse Grou… CAPS Rating: ***
UBS $13.45 Down -0.36 -2.61%
UBS AG (USA) CAPS Rating: **
WFC $44.88 Down -0.86 -1.88%
Wells Fargo CAPS Rating: ****